Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) EBITDA (2016 - 2025)

Historic EBITDA for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$157.7 million.

  • Viking Therapeutics' EBITDA fell 31667.68% to -$157.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$358.5 million, marking a year-over-year decrease of 22481.56%. This contributed to the annual value of -$358.5 million for FY2025, which is 22481.56% down from last year.
  • Per Viking Therapeutics' latest filing, its EBITDA stood at -$157.7 million for Q4 2025, which was down 31667.68% from -$90.2 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' EBITDA registered a high of -$12.7 million during Q4 2021, and its lowest value of -$157.7 million during Q4 2025.
  • Over the past 5 years, Viking Therapeutics' median EBITDA value was -$20.3 million (recorded in 2023), while the average stood at -$33.9 million.
  • Per our database at Business Quant, Viking Therapeutics' EBITDA surged by 608.51% in 2024 and then crashed by 32901.22% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' EBITDA stood at -$12.7 million in 2021, then tumbled by 48.41% to -$18.9 million in 2022, then dropped by 27.46% to -$24.1 million in 2023, then crashed by 57.07% to -$37.8 million in 2024, then tumbled by 316.68% to -$157.7 million in 2025.
  • Its EBITDA was -$157.7 million in Q4 2025, compared to -$90.2 million in Q3 2025 and -$65.5 million in Q2 2025.